RACHEL NEUMOYER: Open Payments
NPI 1801191770 · HAVRE DE GRACE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,495 in 55 payments from 16 companies in 2025. Trend: 2023 $1,842 · 2024 $1,854 · 2025 $1,495
Food & beverage: $1,495
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 6 | $207 |
| Regeneron Healthcare Solutions, Inc. | 6 | $201 |
| Lilly USA, LLC | 3 | $172 |
| Novartis Pharmaceuticals Corporation | 5 | $146 |
| Organon LLC | 12 | $138 |
| GENZYME CORPORATION | 3 | $116 |
| Galderma Laboratories, L.P. | 2 | $107 |
| ABBVIE INC. | 4 | $82 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 3 | $73 |
| LEO Pharma Inc. | 2 | $57 |
Products named: DUPIXENT, Bimzelx, EBGLYSS, Rhapsido, NEMLUVIO, SKYRIZI, ILUMYA, HYRIMOZ.
Industry payments across MD — which companies pay providers there.
